Showing results (711-720 of 1,482) with videos related to
Sort By:
Pageof 149
Human Psychopharmacology|September 15, 2025
The Efficacy and Safety of Amyloid Beta-Directed Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled TrialsYun Wei, Hualing LiHuman Psychopharmacology|May 21, 2025
Clozapine Once-Versus Multiple-Daily Dosing Regimen: A Single-Center, Retrospective, Cross-Sectional StudyJing Ding, Suo Zhang, Huan Xing, et al.Human Psychopharmacology|March 14, 2026
Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis-Application in a Real-World SettingAdrian Heald, Yasitha Illangasekera, Camila Marcelino Loureiro, et al.Human Psychopharmacology|February 17, 2024
Effects of the active botanical blend "WKUP GT" on attention and cognitive functions after lunch in healthy volunteersIrit Schwartz Nadam, Aouatef Bellamine, Rafael Salom, et al.Human Psychopharmacology|April 21, 2026
Enhanced Cardiac Surveillance in Child Psychiatry: Role of Frontal QRS Angle During Atypical Antipsychotic TreatmentDuygu Özge Asena, Duygu Ali, Dilli Gürkan Merve, et al.Human Psychopharmacology|March 31, 2026
Bupropion-Memantine Combination in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionJuan Miguel Riestra, Yaxel Levin-Carrion, Roshan Sutar, et al.Human Psychopharmacology|March 31, 2026
Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTsung-Hsuan Hung, Chyi-Rong Chen, Chih-Wei Hsu, et al.Human Psychopharmacology|May 15, 2026
Underprescription of Clozapine: A Narrative Review Regarding 'Clozaphobia'Rafael Brito Castro, Joaquim J Ferreira, João Gama-MarquesHuman Psychopharmacology|May 15, 2026
Empagliflozin as an Alternative to Metformin for Antipsychotic-Related Weight Gain: Double-Blind Randomized Controlled TrialAtena Dolati, Davoud Ahmadimoghaddam, Maryam Zamanirafe, et al.Human Psychopharmacology|May 15, 2026
Rivastigmine for Behavioural Symptoms in Parkinson's Disease: Evidence and Open QuestionsAntonina LucaPageof 149